Melatonin Versus Placebo for Benzodiazepine Discontinuation in Patients With Schizophrenia
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
In this trial, researchers aim to investigate if prolonged-release melatonin can facilitate
the withdrawal of chronic benzodiazepine administration in patients with schizophrenia.
Furthermore, researchers will investigate the association of benzodiazepine dose reduction
with the following clinically important variables: sleep, psychophysiology, cognition, social
function, and quality of life.
Phase:
Phase 4
Details
Lead Sponsor:
Lone Baandrup
Collaborators:
Copenhagen Trial Unit, Center for Clinical Intervention Research Glostrup University Hospital, Copenhagen